tirzepatide weight loss clinical trial for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Tirzepatide once weekly for the

Qualitative variables were compared using a two-sided chi square test

Dan Wool, NMD | Arizona-licensed Naturopathic Physician | Gastroenterology & Hormone Specialist | 8+ Years Experience Why Choose Medically-Managed GLP-1 Peptide Weight Loss

Tirzepatide (Mounjaro and Zepbound) Eli Lilly developed Tirzepatide, which acts as a dual agonist for GLP-1 and GIP receptors, providing a more potent appetite-suppressing effect

Phase II Clinical Trials: Efinopegdutide (Merck/Johnson & Johnson/Hanmi Hanma), VK2735 (Viking Therapeutics), BGM0504 (BrightGene), Pemvidutide (Altimmune/Spitfire Pharma), AMG133 (Amgen), Dapiglutide (Zealand Pharma), etc

(Its worth noting that this particular studys data were later subject to an expression of concern, so results should be interpreted with some caution

men should seek participation in a registered clinical trial via NIHR Be Part of Research, or discuss currently NICE-approved treatments such as semaglutide or tirzepatide with their GP